Drug Type Trispecific antibody |
Synonyms- |
Target |
Action agonists, antagonists |
Mechanism 4-1BB agonists(Tumor necrosis factor receptor superfamily member 9 agonists), ROR1 antagonists(Inactive tyrosine-protein kinase transmembrane receptor ROR1 antagonists), albumin antagonists(Serum albumin antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | New Zealand | 17 Aug 2024 |